Xenetic Biosciences, Inc. (XBIO) Dividend History

Company News

• Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates

  Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 1.27% and 21.39%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research
• Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue Estimates

  Xenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research

  Featured Companies: AKBA
• Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue Estimates

  Oncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

  Zacks Investment Research
• Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?

  Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  Zacks Investment Research
• Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences

  HC Wainwright has downgraded Xenetic Biosciences Inc (NASDAQ: XBIO) from Buy to Neutral, citing pending clinical path visibility. In the Q1 earnings release, the company announced continued progress with the DNase-based oncology program toward Phase 1 study for pancreatic carcinoma and other locally advanced or metastatic solid tumors. Xenetic announced a one-for-ten reverse stock split, the second ...Full story available on Benzinga.com

  Benzinga